Improving IL-15 antitumor efficacy: fusion protein strategy

  • Apolipoprotein A‐I (Apo‐AI) is the major protein constituent of the HDL particles.

  • Apo‐AI fusion proteins have an optimized pharmacokinetic/pharmacodynamic profile as they show the following properties:

    • Apo‐AI increases the plasmatic half‐life and the liver retention of the fused proteins.

    • Blood‐brain barrier active transport, mediated by a saturable transporter that limits the amount of the fusion protein in the central nervous system.

    • Modulation of activity: Apo‐AI activates MAPKs through ABCA1 and SR‐BI and, therefore, modulates the therapeutic effect of fused proteins.

  • pSushi‐IL‐15‐Apo is a new proprietary triple fusion protein developed combining apolipoprotein AI, IL‐15 and IL‐15Rα's sushi, with:

    • Superior antitumor effect than IL‐15 as a single agent.

    • Higher capacity than hIL15 to enhance antibody dependent cell cytotoxicity (ADCC) when combined with monoclonal antibodies.

    • Increased stability in circulation.

    • Facilitated trans‐presentation.

  • Primary Indication: adjuvant of tumor specific antigen antibodies in lymphoma, breast cancer and colorectal cancer treatment.

​>> Download more information

New biomarker for lung cancercomplement activation fragment C4d

  • Lung cancer is the leading cause of cancer death worldwide.

  • Lung cancer is often detected at advanced stages. No diagnostic marker has been proven useful in lung cancer clinical practice. The unmet need for lung cancer diagnostic tools is considered high.

  • C4d, a complement activation fragment, has been identified as a new biomarker for the early diagnostic or prognostic evaluation of lung cancer patients.

  • Indication: lung cancer

    • new molecular marker in risk algorithms.

    • patient selection for invasive procedures.

>> Download more information

New expression profile: prognosis of early stage lung cancer

  • Lung cancer is the leading cause of cancer death worldwide.

  • Prognostic markers may guide treatment decisions to improve survival of patients with lung cancer.

  • RNA metabolism score is a five‐gene expression signature for the prognostic evaluation of patients with early stage lung cancer.

  • Indication: to determine the risk of recurrence in surgically‐treated lung cancer patients.

>> Download more information


Programas de investigación

Programas de investigación en los que puede participar con el CIMA

Acuerdos y programas de investigación del CIMA [PDF]

"CIMA Lab Diagnostics"


Su objetivo es optimizar con el máximo nivel de calidad e innovación el abanico de diagnósticos genéticos e inmunofenotípicos que se desarrollan en diferentes laboratorios de la Universidad de Navarra.

Ir a empresas

Contacta con nosotros

Contacto:
Centro de Investigación Médica Aplicada (CIMA)
Avenida Pío XII, 55
31008 Pamplona
España

+34 948 194700
cima@unav.es